Effects of aerobic training and semaglutide treatment on pancreatic β-cell secretory function in patients with type 2 diabetes
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Effects of aerobic training and semaglutide treatment on pancreatic β-cell secretory function in patients with type 2 diabetes. / Ingersen, Arthur; Schmücker, Malte; Alexandersen, Christina; Graungaard, Benjamin; Thorngreen, Tobias; Borch, Jacob; Holst, Jens Juul; Helge, Jørn Wulff; Dela, Flemming.
I: Journal of Clinical Endocrinology and Metabolism, Bind 108, Nr. 11, 2023, s. 2798–2811.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Effects of aerobic training and semaglutide treatment on pancreatic β-cell secretory function in patients with type 2 diabetes
AU - Ingersen, Arthur
AU - Schmücker, Malte
AU - Alexandersen, Christina
AU - Graungaard, Benjamin
AU - Thorngreen, Tobias
AU - Borch, Jacob
AU - Holst, Jens Juul
AU - Helge, Jørn Wulff
AU - Dela, Flemming
N1 - © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
PY - 2023
Y1 - 2023
N2 - OBJECTIVE: The effect of the interaction of semaglutide and physical training on pancreatic β-cell secretory function is unknown in patients with type 2 diabetes.RESEARCH DESIGN AND METHODS: Thirty-one patients with type 2 diabetes underwent 12 weeks of aerobic training alone or concurrent to treatment with semaglutide. Patients randomly allocated to concurrent semaglutide and training were treated with semaglutide for 20 weeks before the training and evaluated at inclusion and again before and after the training intervention. Patients randomised to training were evaluated before and after training. The primary outcome was a change in insulin secretory capacity with training, evaluated by a two-stepped hyperglycemic (20 and 30-millimolar) clamp.RESULTS: Training increased the incremental area under the curve for insulin from 21 to 27 nanomolar • 2h (ratio 1.28 (95% confidence interval [CI] 1.02-1.60) during clamp step 1 and from 40 to 64 nanomolar • 2h (ratio 1.61, 95% CI 1.25-2.07) during step 2. Semaglutide treatment increased insulin secretion from 16 to 111 nanomolar • 2h (ratio 7.10, 95% CI 3.68-13.71), and from 35 to 447 nanomolar • 2h (ratio 12.74, 95% CI, 5.65-28.71), correspondingly. Semaglutide and training increased insulin secretion from 130 to 171 nanomolar • 2h (ratio 1.31, 95% CI 1.06-1.63), and from 525 to 697 nanomolar • 2h (ratio 1.33, 95% CI 1.02-1.72), correspondingly. The median increase in total insulin secretion with the combination was 134 nanomolar • 2h greater (95% CI 108-232) than with training.CONCLUSIONS: The combination of aerobic training and semaglutide treatment synergistically improved β-cell secretory function. (ClinicalTrials.gov number, ID NCT04383197).
AB - OBJECTIVE: The effect of the interaction of semaglutide and physical training on pancreatic β-cell secretory function is unknown in patients with type 2 diabetes.RESEARCH DESIGN AND METHODS: Thirty-one patients with type 2 diabetes underwent 12 weeks of aerobic training alone or concurrent to treatment with semaglutide. Patients randomly allocated to concurrent semaglutide and training were treated with semaglutide for 20 weeks before the training and evaluated at inclusion and again before and after the training intervention. Patients randomised to training were evaluated before and after training. The primary outcome was a change in insulin secretory capacity with training, evaluated by a two-stepped hyperglycemic (20 and 30-millimolar) clamp.RESULTS: Training increased the incremental area under the curve for insulin from 21 to 27 nanomolar • 2h (ratio 1.28 (95% confidence interval [CI] 1.02-1.60) during clamp step 1 and from 40 to 64 nanomolar • 2h (ratio 1.61, 95% CI 1.25-2.07) during step 2. Semaglutide treatment increased insulin secretion from 16 to 111 nanomolar • 2h (ratio 7.10, 95% CI 3.68-13.71), and from 35 to 447 nanomolar • 2h (ratio 12.74, 95% CI, 5.65-28.71), correspondingly. Semaglutide and training increased insulin secretion from 130 to 171 nanomolar • 2h (ratio 1.31, 95% CI 1.06-1.63), and from 525 to 697 nanomolar • 2h (ratio 1.33, 95% CI 1.02-1.72), correspondingly. The median increase in total insulin secretion with the combination was 134 nanomolar • 2h greater (95% CI 108-232) than with training.CONCLUSIONS: The combination of aerobic training and semaglutide treatment synergistically improved β-cell secretory function. (ClinicalTrials.gov number, ID NCT04383197).
U2 - 10.1210/clinem/dgad326
DO - 10.1210/clinem/dgad326
M3 - Journal article
C2 - 37265222
VL - 108
SP - 2798
EP - 2811
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 11
ER -
ID: 350976677